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Acute Coronary Syndrome
Emerging Tools for Diagnosis and Risk Assessment
Benjamin M. Scirica, MD, MPH
Boston, Massachusetts
Acute coronary syndrome encompasses a broad and heterogeneous population that challenges the clinician at
each step of treatment in terms of: 1) diagnosis; 2) appropriate risk stratification; 3) therapeutic decision mak-
ing; and 4) monitoring response to therapy. Although there are many established tools for diagnosis, prognosis,
and clinical decision making, understanding the advantages and limitations of each tool according the clinical
scenario is essential. Several emerging tools, such as novel biomarkers (e.g., high-sensitivity troponin and
growth differential factor-15), ECG techniques (e.g., heart rate turbulence or T-wave alternans), and imaging mo-
dalities (computed tomography angiography and cardiac magnetic resonance) may potentially improve clinical
care; however, they must be fully evaluated and validated in different scenarios and patient cohorts before they
are incorporated into clinical practice. This review identifies promising new or emerging techniques, as well as
established tools, and reviews their current or potential role in clinical practice. (J Am Coll Cardiol 2010;55:
1403–15) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.071E
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rcute coronary syndrome (ACS) encompasses a broad and
eterogeneous population ranging from a patient with
typical chest discomfort, nonspecific electrocardiographic
ECG) changes, and normal cardiac biomarkers to the
atient with a large ST-segment elevation, myocardial
nfarction (MI), and cardiogenic shock.
The diversity in clinical presentation of patients with
uspected acute ischemic symptoms challenges the physician
t each step of treatment in terms of: 1) diagnosis of ACS;
) appropriate risk stratification; 3) therapeutic decision
aking; and 4) monitoring response to therapy (Fig. 1).
hen approaching a patient with suspected ACS, clinicians
ncorporate all available data to create a treatment plan. The
ases for these decisions, even those that adhere to clinical
uidelines, often rely on less than definitive data (1). The
im of this article is first to briefly review the statistical and
nalytical underpinnings that are used to evaluate new and
merging techniques for diagnosis, prognosis, and medical
ecision making and then to review how the clinical history,
lectrocardiography, biomarkers, and imaging modalities
ay be incorporated into clinical care.
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iagnosis. In the simplest terms, the goal of diagnosis is
o correctly identify (or discriminate) patients with and
ithout a particular disease. Diagnostic tests are evalu-
ted according to their sensitivity (probability of a posi-
ive test result in a person with the disease) and specificity
probability of a negative test result in a person without
he disease) and then compared with a gold standard. By
ncorporating both sensitivity and specificity, one can
stimate likelihood ratios, receiver-operator characteristic
urves, and overall accuracy to best understand the
erformance of a particular diagnostic test (2).
There are 2 related, although distinct, diagnostic
uestions in ACS. First, does the patient actually have
nstable ischemic symptoms as opposed to nonischemic
r noncardiac symptoms? Evaluating tools to identify
atients with ACS without evidence of myocardial ne-
rosis remains problematic because there is no true gold
tandard for the diagnosis of unstable angina. In contrast,
he second question, did the patient have an MI, is more
learly defined according to consensus definitions based
n the clinical scenario and the identification of myocar-
ial necrosis by elevated levels of cardiac troponin (3)
Fig. 2).
rognosis/risk stratification. Estimating prognosis is, by
efinition, based on probability and intends to predict
uture outcomes using clinical models that incorporate
nown risk features. Estimating, or discriminating, the
elative strength of the relationship between clinical
ariables and clinical outcomes can be done using several
iA
u
r
n
e
T
n
o
t
w
t
t
i
t
t
t
i
t
o
e
w
t
C
C
fi
A
w
s
l
D
i
r
s
A
c
m
P
o
d
c
f
r
a
s
c
M
s
a
a
E
l
C
a
e
g
S
s
i
w
N
b
w
t
e
(
b
t
t
a
r
c
m
g
s
o
1404 Scirica JACC Vol. 55, No. 14, 2010
ACS: Diagnosis and Risk Assessment April 6, 2010:1403–15statistical techniques based on
the addition of different risk
variables to an accepted model.
Traditionally, Cox models and
receiver-operator characteristic
curves have been used to iden-
tify variables independently as-
sociated with outcomes or to
improve discrimination as de-
termined with an increase in
the C-statistic. However, these
statistical techniques may un-
derestimate the significance of a
new variable in predicting rela-
tively infrequent events such as
cardiovascular death and recur-
rent ischemic episodes (2,4).
Several new methods, such as
integrated discriminating index
(IDI), and net reclassification
improvement (NRI), or reclas-
sification calibration statistic,
attempt to improve the integra-
tion of sensitivity and specific-
ity and evaluate the proportion
of patients who are reclassified
to higher or lower risk catego-
ries based on a new technique
(5). New risk stratification al-
gorithms should be evaluated
using several tests of discrimi-
nation and calibration, includ-
ng these newly described techniques.
All guidelines strongly recommend that patients with
CS be accurately categorized into different risk categories
sing clinical models, but there remains substantial debate
egarding the optimal method for determining whether a
ew risk factor improves the discrimination of future cardiac
vents (2,4,6).
herapeutic implications/clinical decision making. The
ext and perhaps most challenging step in the evaluation
f a new clinical technique is to determine whether using
hat tool changes practice based on its result. In other
ords, does the knowledge of the results of a particular
est alter the treatment? The identification of a treatment
hat is of particular benefit in one group versus the other
s most commonly identified within clinical trials when
here is documented evidence of heterogeneity in the
reatment effect based on a positive interaction between
reatment and the clinical variable of interest. Confirm-
ng the relationship should then be evaluated prospec-
ively in studies that specifically identifies patients based
n that feature (e.g., cardiogenic shock, diabetic patients,
levated clinical risk score or troponin) to determine
hether the proposed treatment improves outcomes in
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CAD  coronary artery
disease
CK-MB  creatine kinase-
myocardial bound
CMR  cardiac magnetic
resonance
CRP  C-reactive protein
CTA  computed
tomography angiography
ECG  electrocardiographic
GDF  growth
differentiation factor
HRT  heart rate
turbulence
HRV  heart rate variability
MDCT  multidetector
computed tomography
MI  myocardial infarction
MPI  myocardial perfusion
imaging
NP  natriuretic peptide
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
STEMI  ST-segment
elevation myocardial
infarctionhat population. clinical History and Evaluation
linical evaluation is fundamental to diagnosis, risk strati-
cation, and decision making in patients with suspected
CS. The most important step in the evaluation of a patient
ith suspected ACS is to determine whether the clinical
cenario is consistent with a spontaneous atherothrombotic
esion.
iagnosis. Despite the advances in imaging and biochem-
cal markers, obtaining a complete and detailed history
emains the cornerstone of the evaluation of patients with
uspected ischemic coronary syndromes. A diagnosis of
CS can be made based solely on history if there is a
ompelling clinical scenario in a patient with at least a
oderate or high probability of an unstable syndrome.
rognosis. Many clinical features assessed at presentation
ffer important prognostic information regarding the risk of
eath, MI, heart failure, or arrhythmic complications. Killip
lass, for example, which classifies the degree of heart
ailure, is one of the most powerful indicators of in-hospital
isk. Clinical features, when combined with basic laboratory
nd ECG findings, have been incorporated into clinical risk
cores that accurately stratify patients into different risk
ategories. The most widely used are the Thrombolysis In
yocardial Infarction (TIMI) risk score for non–ST-
egment elevation acute coronary syndrome (NSTE-ACS),
nd ST-segment elevation myocardial infarction (STEMI),
nd the GRACE (Global Registry of Acute Coronary
vent) risk score, which have all been derived or validated in
arge registry databases (7–9).
linical implications. Treatment decisions are often and
ppropriately based solely on the clinical evaluation. For
xample, according to the SHOCK (Should We Emer-
ently Revascularize Occluded Coronaries for Cardiogenic
hock) trial, patients with ACS and evidence of cardiogenic
hock benefit from immediate revascularization versus med-
cal therapy (10). Clinical risk scores also identify patients
ho benefit from more aggressive treatment. Patients with
STE-ACS with a moderate or high TIMI risk score have
een shown to have a greater benefit with low molecular
eight heparin (7), an early invasive strategy (11), and with
he use of a glycoprotein IIb/IIIa inhibitors (12).
Current guidelines recommend calculating risk scores to
valuate risk and guide treatment decisions accordingly
13,14). Clinicians, however, tend to underestimate risk
ased on clinical evaluation. In the Canadian ACS Registry,
reating physicians classified patients by their own estima-
ion into low-, intermediate-, or high-risk groups. Patients
t higher risk as determined by the treating physician did
eceive more aggressive therapy; however, there was poor
orrelation between physician-estimated risk and risk deter-
ined by the TIMI, GRACE, or PURSUIT (Platelet
lycoprotein IIb/IIIa in Unstable angina: Receptor Suppres-
ion Using Integrilin) risk scores (15). All 3 risk scores
ffered better discrimination in terms of predicting out-
omes compared with the treating physician’s classification
(
i
b
S
r
a
p
f
E
T
m
a
c
t
t
F
a
a
n
D
fi
o
f
s
r
e
t
S
d
o
V
e
e
8
t
1405JACC Vol. 55, No. 14, 2010 Scirica
April 6, 2010:1403–15 ACS: Diagnosis and Risk Assessment16). Underestimation of risk was primarily due to discount-
ng the significance of older age and previous coronary artery
ypass graft, and an overemphasis on biomarkers and
T-segment depressions. One-third of all patients were not
eferred for catheterization because they were thought to be
t “not high enough risk.” In fact, almost 60% of these
atients were in an intermediate or high TIMI risk category,
or which an invasive strategy is recommended (17).
lectrocardiography
he standard 12-lead electrocardiogram remains the single
ost important diagnostic tool in the evaluation of ACS
nd as such should be performed within 10 min of the first
ontact with medical personnel. The integrated role of that
he admission electrocardiogram plays in the diagnosis,
riage, and treatment of patients with ACS is shown in
igure 1. In addition, continuous ECG monitoring after
Figure 1 Application of Clinical Techniques in Patients With Su
Ideally, a clinical tool is useful for diagnosis, risk stratification, clinical decision m
of each stage of clinical use. The 12-lead electrocardiogram (ECG) is one exceptio
prognosis (19), clinical decision making (fibrinolytics in patients with STEMI [ST-se
resolution [STR] [25]). ACS  acute coronary syndrome; CV  cardiovascular; ICD
cardiac death.dmission may provide additional information regarding irrhythmia or recurrent ischemia and can be used for more
ovel and complex analyses (Table 1).
iagnosis. The presence of ST-segment elevation identi-
es the first branch point in the identification and diagnosis
f ACS. ST-segment elevation is the most specific finding
or MI and, together with a compatible clinical scenario, is
ufficient to make the diagnosis of MI. Any question
egarding the diagnosis of STEMI can be confirmed with
chocardiography to assess wall motion abnormalities. Al-
hough not specific enough to be diagnostic for MI,
T-segment depression, especially if dynamic and captured
uring ischemic symptoms, greatly increase the likelihood
f ACS. Capturing additional leads (right-sided and V7 to
9) improves both the sensitivity and specificity of the
lectrocardiogram in the diagnosis ACS and MI. More
xtensive monitoring with body surface mapping with
0-lead electrocardiograms has also been shown to improve
he detection of myocardial ischemia, in particular, for
ted ACS
and monitoring therapy. Few existing tools address the statistical requirements
is central to each stage via diagnosis, in this example with ST-elevation (STE),
elevation myocardial infarction]), and monitoring therapy (degree of ST-segment
lantable cardioverter-defibrillator; MI  myocardial infarction; SCD  suddenspec
aking,
n and
gment
 impschemia in high right anterior, posterior, and right ventric-
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ACS: Diagnosis and Risk Assessment April 6, 2010:1403–15lar territories (18). Whether a patient has unstable angina
r non-STEMI will depend on any elevation in markers of
ecrosis.
rognosis. ST-SEGMENTS. In addition to aiding in diagno-
is, different aspects of the electrocardiogram also provide
rognostic information (19,20). Patients with NSTE-ACS
nd ST-segment deviation 0.5 mV were at greater 1-year
isk of death or MI than patients with T-wave inversion or
o ECG changes (21). Even when including cardiac bio-
arkers such as troponin, N-terminal pro–B-type natri-
retic peptide (NP), and C-reactive protein (CRP), the
egree of ST-segment depression in patients with
STE-ACS was the strongest prognostic variable for
eath or MI (22).
Continuous ECG monitoring in patients hospitalized
ith ACS allows detailed assessment of recurrent ischemia.
n more than 6,300 patients with NSTE-ACS who under-
ent 7-day continuous ECG monitoring, an episode of
ecurrent ischemia (1 mm depression lasting at least 1
in) was associated with a significant increase in the risk of
schemic events including cardiovascular death. Patients
ith more than 2 episodes were at greatest risk, and the
ssociation was similar regardless of medical therapy or
evascularization during the index hospitalization (23).
T-SEGMENT RESOLUTION AFTER FIBRINOLYSIS. In pa-
ients with STEMI, close monitoring of the ST-segment
fter reperfusion provides a noninvasive method of assessing
Figure 2 Incorporation of Clinical, Electrocardiographic, Bioma
Diagnosis of suspected acute coronary syndrome (ACS) begins with the clinical ev
tests with different sensitivities and specificities should be used to confirm or reje
scenario to determine whether it is an ACS-related MI (type 1 or spontaneous) or
NPV  negative predictive value.eperfusion after fibrinolysis and the degree of ST-segment desolution after reperfusion is closely associated with prog-
osis. Patients with failed reperfusion detected as poor
T-segment resolution should be urgently triaged to more
ntensive medical and interventional procedures (22). As
escribed by deLemos et al. (24) and Schröder et al. (25,26),
he degree of maximal ST-segment deviation on presenta-
ion and the extent ST-segment resolution after reperfusion
re independent indicators of short- and long-term out-
omes. ST-segment resolution after primary percutaneous
ntervention has also been associated with worse outcomes,
lthough the therapeutic implication is not well defined.
OVEL ELECTROCARDIOGRAPHIC PARAMETERS. Standard
valuation of the electrocardiogram is limited mostly to
dentifying the underlying cardiac rhythms and recognizing
he typical wave patterns of cardiac ischemia. The ECG
ignal, however, provides a vast amount of additional data
n the overall health of the heart that is currently not
xtracted because clinicians lack the tools and technology to
nterpret subtle abnormalities. Several ECG techniques
uch as heart rate variability (HRV) (27), deceleration
apacity (28), heart rate turbulence (HRT) (29), T-wave
lternans (30–32), and signal-averaged electrocardiography
31), among others, have been proposed to evaluate different
spects of ECG signals.
As opposed to ST-segment and T-wave deviations,
hich assess ischemia, these novel ECG metrics primarily
ttempt to identify patients at greatest risk of arrhythmic
and Imaging Data in the Diagnosis of ACS and MI
n and decision regarding the likelihood of ACS. Depending of that likelihood,
diagnosis. The diagnosis of myocardial infarction (MI) must incorporate clinical
S-related myonecrosis (type 2 or secondary). ECG  electrocardiogram;rker,
aluatio
ct the
non–ACeath and thus focus on overall mortality and sudden cardiac
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April 6, 2010:1403–15 ACS: Diagnosis and Risk Assessmenteath rather than recurrent ischemic events (33). Most
tudies therefore focus on patients with the greatest risk of
udden cardiac death, in particular, patients with a history of
I and heart failure or depressed left ventricular function.
RV, HRT, deceleration capacity, signal-averaged electro-
ardiography, and T-wave alternans have all been shown to
e associated with increased overall mortality or sudden
ardiac death.
HRT, which assesses autonomic tone on heart rate
ecovery after premature ventricular beats, has been shown
n more than 6,000 patients with a recent MI to be closely
ssociated with mortality, even after adjusting for clinical
eatures. The predictive accuracy of HRT was similar to left
entricular ejection fraction in terms of predicting sudden
ardiac death (29). Other ECG techniques, such as decel-
ration capacity, which focuses principally on the vagal
ather than sympathetic compenents of HRV, also have
ood discrimination for identifying patients at high risk of
eath after MI (C-statistic improvement from 0.74 to 80),
hich was better than an ejection fraction 30% or stan-
ard HRV parameters (28). Further studies to best assess
he predictive value of novel ECG techniques are needed.
linical implications. The identification of ST-segment
levation or a new left bundle branch block is one the most
traightforward examples of how a diagnostic test drives
linical decision making. Few other findings are quite as
stablished and Novel BiomarkersTable 1 Established and Novel Biomarkers
Biomarkers
Troponin Necrosis
Natriuretic peptides Ventricular stress
Creatine kinase-myocardial bound Necrosis
Myoglobin Necrosis
High-sensitivity troponin Necrosis/ischemia
Ischemia-modified albumin Ischemia
Fatty acid binding protein Ischemia
Growth differential factor-15 Ischemia/reperfusion
C-reactive protein Inflammation: nonspecific marker
Pregnancy-associated plasma protein-A Inflammation: matrix
metalloproteinase-9/plaque instabilit
Myeloperoxidase Inflammation: neutrophil activation,
reactive oxygen species
ST2 Inflammation: regulatory protein in time
of myocardial stress
Lysosomal phospholipase A2 Cholesterol trafficking
Copeptin Stress: vasopressin prohormone
Soluble CD40 ligand Platelet activation
Fibrinogen Thrombosis
Plasminogen activator inhibitor-1 Endogenous fibrinolytic system
D-Dimer Thrombosis
Platelet aggregation 2 Response to antiplatelet therapy
CYP2C19 polymorphism 2 Response to clopidogrel
Metabolite profile Early signs of metabolic dysregulation
CS  acute coronary syndrome; MI  myocardial infarction;   limited or contradictory evidentraightforward in cardiology. Similarly, although not as lpecific, dynamic ST-segment depressions or transient ST-
egment elevations are high-risk features that should
rompt more aggressive medical and invasive therapy in
atients with NSTE-ACS (13,14).
Although there has been great hope in developing an
CG parameter to guide therapy and identify patients at
reatest risk of sudden cardiac death, none of the novel
CG parameters such as HRT, deceleration capacity, or
ven T-wave alternans have conclusively been shown to
rovide information that should alter therapy. Adequately
owered trials that prospectively identify patients according
o a novel high-risk feature (e.g., low HRT or increased
-wave alternans) followed by randomization to therapy
e.g., implantable cardioverter-defibrillator placement or
ntiarrhythmic therapy) are needed to define whether these
ew techniques should be incorporated into clinical care
34,35).
iomarkers
he discovery and evaluation of cardiac biomarkers contin-
es at a rapid pace. Two biomarkers—cardiac troponin and
Ps—have been fully incorporated into clinical care for
any years; however, there remains substantial confusion
egarding their application in ACS with regards to diagnosis
nd clinical decision making (3,36). Moreover, there are
Diagnosis
Prognosis
Clinical
Implications
Monitor
Therapy
ACS (Without Evidence of
Myocardial Necrosis) MI
   
   
   
  
  
 
 
  
  

 
 
  
 
 
 

 
  
 
 
 compelling but not conclusive evidence;   strong/validated evidence for use.y
siterally dozens of additional biomarkers reflecting different
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ACS: Diagnosis and Risk Assessment April 6, 2010:1403–15hysiologic pathways that have been proposed to improve
iagnosis or prognosis (Table 2).
ardiac troponin. DIAGNOSIS. An elevated concentration
f cardiac troponin is central to the universal definitions of
I. Values that are above the 99th percentile of a normal
opulation should be considered as an indication of myo-
ardial necrosis (3). Ideally, an assay should have a precision
or imprecision) of10% coefficient of variation at the 99th
ercentile level. Despite a clear consensus on the definition
f MI that is based on elevated cardiac troponin, several
actors still lead to substantial confusion in clinical practice.
First, there are multiple commercially available assays,
ach with an individual decision limit based on the assay’s
erformance. Second, many laboratories still report several
ut points, often labeling them “normal,” “indeterminate,”
nd “suggestive of myocardial injury.” With the current
eneration of commercial assays, there should be no “inde-
erminate” values, only results above or below the specific
ssay cut point. The third area of confusion is the most
linically challenging and due to the widespread use of
roponin assays in a broader population than patients with
uspected ACS. Cardiac troponins are extremely specific for
ardiac injury; however, myocardial damage is not specific to
CS. Central to the diagnosis of ACS and MI is a clinical
cenario consistent with myocardial ischemia. Thus, an
levated troponin in a patient with sepsis, hypertensive
mergency, or pulmonary embolism indicates that there has
een myocardial damage—type 2 or secondary MI as defined
y the Universal Definition of MI—and likely indicates a
orse prognosis, but it does not mean that patient has ACS
nd therefore should not receive ACS-directed care. Over-
eliance on troponin as a diagnostic tool can lead to
isdiagnosis and inappropriate, and potentially dangerous,
reatment. Conversely, in a patient with a clinical scenario
stablished and Emerging Electrocardiographic ToolsTable 2 Established and Emerging Electrocardiographic Tools
Electrocardiographic Test
12-lead electrocardiogram
ST-segment elevation Injury current
Dynamic ST-segment depression Ischemia
Dynamic T-wave changes Ischemia
Continuous electrocardiographic monitoring
ST-segment shift Ischemia
Ventricular ectopy Arrhythmia
Heart rate variability Autonomic nervous system
modulation of sinus node
Deceleration capacity Vagal modulation of sinus node
Heart rate turbulence Short-term fluctuation of sinus
cycle after VPB; possibly
reflects baroreflex sensitivity
T-wave alternans Repolarization abnormalities
Signal-averaged electrocardiography QRS variability and late potentials
Morphologic variability Beat-to-beat energy differences
PB  ventricular premature beat; other abbreviations as in Table 1.onsistent with myocardial ischemia, an elevated troponin, even at levels just above the 99th percentile, fulfills the
riteria for MI (type 1 or spontaneous MI) and identifies a
atient who should be treated accordingly.
In patients presenting with ACS, creatine kinase-
yocardial bound (CK-MB) should not be used for diag-
ostic purposes if troponins are also measured. Given the
ensitivity and specificity of troponin for myocardial dam-
ge, elevated CK-MB in the setting of a normal troponin
ndicates a false-positive CK-MB. Both CK-MB and tro-
onin can be used to detect episodes of reinfarction if the
iomarker increases 20% above the level measured at the
ime of the recurrent symptoms (3).
IGH-SENSITIVITY TROPONIN ASSAYS. There are several
ew troponin assays under development with reported
etection limits and reproducibility that are considerably
etter than the current commercially available assays
37–39). These high-sensitivity assays detect pg/ml as op-
osed to ng/ml levels of circulating troponin and offer the
ossibility of not only greater sensitivity in identifying
yocardial necrosis but also earlier detection. For example,
n a study of patients with documented myocardial injury,
4% of the initial samples with negative results using a
tandard troponin assay actually had detectable levels of
roponin using one of the high-sensitivity assays (37). In 2
tudies of patients presenting with chest pain, several
igh-sensitivity troponin assays demonstrated impressive
mprovements in the diagnostic accuracy for MI, in partic-
lar among patients who presented early after the onset of
ymptoms. For example, 1 high-sensitivity assay improved
he c-statistic for MI from 0.85 to 0.96 compared to a
tandard troponin assay (40,41).
The incorporation of high-sensitivity assays into clinical
are will require a considerable amount of research and
Diagnosis
Prognosis
Clinical
Implications
Monitor
Therapy
S (Without Evidence of
Myocardial Necrosis) MI
    
    
    
  
  



 

ACducation. High-sensitivity assays will increase the sensitiv-
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April 6, 2010:1403–15 ACS: Diagnosis and Risk Assessmentty for detecting myocardial injury, but will reduce specificity
or identifying ACS. Many more patients with an ischemic
yndrome will have detectable levels of troponin and thus
ulfill the criteria for MI. Placing the laboratory data within
he clinical context will become even important because a
reater number of patients without ACS will also have
etectable levels of troponin due to other etiologies such as
eart failure, renal disease, or myocarditis (type 2 or sec-
ndary MI). Moreover, due to the greater sensitivity in
etecting even lower concentrations of circulating troponin,
dentifying the appropriate cut point will be dependent on
he makeup of the “healthy” population and could differ
ignificantly from one cohort to another. The recommen-
ations in the current universal MI definition to evaluate the
attern of serial troponin measurements in patients with
ersistently elevated levels (e.g., renal failure) will become
ven more relevant with the introduction of highly sensitive
roponin assays that will identify even more patients with
etectable basal levels of troponin (3,42).
The development of more sensitive troponin assays may
lso require a reassessment of the currently held belief that
roponin is only released from permanently injured myocar-
ial cells. In a study of 120 patients referred for exercise
tress testing, transient stress-induced ischemia, as detected
y nuclear imaging, was associated with a detectable in-
rease in troponin using one of the new high-sensitivity
ssays. There was no corresponding increase detected with
onventional troponin assays (43). The entire paradigm of
roponin “positive” or “negative” in ACS may need to
hange if and when high-sensitivity assays become commer-
ially available.
rognosis. Myocardial damage, as detected by elevated
evels of cardiac troponin, clearly increases the risk of
ecurrent cardiovascular events with a graded relationship
etween the absolute elevation and outcomes. Overall, an
levated troponin is associated with roughly a 4-fold in-
rease in the risk of death or recurrent MI compared with
atients with a normal troponin concentration (44–46).
ardiac troponin is complementary to other risk factors
uch as age, renal function, and ECG changes. Even among
atients with STEMI in whom biomarkers should not be
sed for diagnostic purposes, elevated troponin on admis-
ion is associated with worse outcomes (47,48), and peak
roponin concentrations correlate with infarct size as deter-
ined by nuclear imaging (49).
Even low-level troponin elevations, at concentrations below
hat would be considered an appropriate MI cut point, are
ssociated with worse clinical outcomes. Several studies of
atients with chest pain or NSTE-ACS have shown that
atients with initial concentrations of troponin that were
etectable but still below the 99th percentile/10% coefficient
f variation MI cut point were at greater risk of death or
ecurrent MI compared with patients with concentrations
elow the lower limit of detection (50,51).
As more sensitive troponin assays are introduced, furtheresearch regarding the prognostic risk associated with ex- tremely small troponin elevations will be needed; however, it
s likely that any elevation in troponin will likely identify
atients at greater risk compared to patients with a nonde-
ectable level.
LINICAL IMPLICATIONS. Together with the initial electro-
ardiogram, cardiac troponin is one of the central decision-
aking nodes in the treatment of patients with ACS.
schemia severe enough to induce necrosis is typically the
esult of more complex and thrombotic coronary lesions
52,53), and not unexpectedly, patients with elevated con-
entrations of troponin derive the greatest benefit from
ore aggressive antithrombotic therapy with low molecular
eight heparins and the glycoprotein IIb/IIIa inhibitors
13,14) Several studies in patients with NSTE-ACS have
hown that patients with elevated levels of troponin receive
he greatest benefit from an invasive strategy compared with
atients with no detectable necrosis, although 1 trial, the
CTUS (Invasive Versus Conservative Treatment in Unsta-
le Coronary Syndromes) trial, prospectively enrolled pa-
ients with NSTE-ACS and an elevated troponin and did
ot demonstrate any benefit of an early invasive strategy
ompared with initial medical management, although there
as high crossover to catheterization from the medical
herapy group (54). Overall, a meta-analysis of 7 trials
omparing an invasive and conservative strategies, which
ncluded the ICTUS trial, did demonstrate an overall
eduction in short- and long-term outcomes with an inva-
ive strategy (55), and current guidelines recommend this
trategy in patients at high risk based on elevated levels of
roponin. With the introduction of higher sensitivity tro-
onin assays, many of the treatment implications associated
ith elevated levels of troponin, including early invasive
trategy, will require re-evaluation.
Ps. NPs are released from the ventricular myocardium in
esponse to stress. There are commercially available assays
or both B-type NP and N-terminal-pro–B-type NP, and
lthough there are differences in terms of kinetic and
nalytic parameters, their clinical role can be addressed
ogether.
IAGNOSIS. As a marker of myocardial stress, NPs are
levated in many cardiovascular conditions, most commonly
eart failure, but also pulmonary hypertension, pulmonary
mbolism, cardiac arrhythmias, and cardiac ischemia. Thus,
s a diagnostic tool, NP is sensitive but lacks specificity to
ither include or exclude patients with ACS.
ROGNOSIS. Among patients with ACS, elevated levels of
P are strongly associated with clinical outcomes across the
pectrum of ACS (56) including NSTE-ACS (57) and
TEMI (58,59). NP levels typically peak in the hours after
he initiation of an ACS episode and then gradually
ecrease over the subsequent days; however, the pattern and
peed of decrease are not uniform. Persistently elevated
evels of an NP in the days and weeks following ACS may
hen identify patients at particularly high risk of cardiovas-
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ACS: Diagnosis and Risk Assessment April 6, 2010:1403–15ular death or heart failure, even in the setting of normal
jection fraction (60–62).
LINICAL IMPLICATIONS. In contrast to troponins and de-
pite the ample evidence linking elevated levels of NP and
ardiovascular outcomes, there are no clear clinical implica-
ions of how an elevated NP level should guide specific
herapy or treatment in ACS (36). In terms of deciding on
n early invasive strategy, one study found a nonsignificant
rend toward greater benefit in patients with elevated levels
f NP (63); however, another found no difference in the
enefit of an early invasive versus compared with medical
herapy (64). Studies specifically designed to evaluate
hether a specific strategy or medication targeted at patients
ith an elevated NP level can modify the associated risk, or
etermine if NPs are useful to monitor therapy, are needed
o better define the utility of routine measurement of the
P level in ACS (36).
RP. CRP, a nonspecific marker of inflammation, has
een evaluated extensively in ACS. Although not specific
nough to aid in the diagnosis of ACS or MI, elevated levels
f CRP at the time of admission have been shown in
ultiple studies to be associated with poor outcomes in
atients with ACS (36,65,66). The strength of that rela-
ionship varies depending of the degree of myocardial
ecrosis, the cut point applied, the timing of measurement,
nd the patient population (36). CRP may be most useful
hen it is measured soon after the index event where the
nflammation represents the underlying inflammatory pre-
ipitant as opposed to later when it may be confounded by
ecrosis, and when using disease-specific cut points (67).
ssessing levels of CRP several weeks after ACS, when the
cute inflammatory phase has subsided, may be more useful
han in the acute setting. Patients with a CRP level2 mg/l
month after admission for ACS were at significantly
reater risk of death (68,69) and heart failure (62) compared
ith those with a low levels of CRP. The strategy of
argeting patients with elevated concentrations of CRP with
pecific therapy, as was done in the primary prevention
UPITER (Justification for the Use of Statins in Primary
revention: An Intervention Trial Evaluating Rosuvasta-
in), is an example of how novel risk markers should be
rospectively evaluated (70).
ovel biomarkers. There are literally dozens of biomarkers
eflecting a variety of pathophysiologic pathways that have
een reported to be elevated in patients with ACS and
otentially associated with increased risk. These include mark-
rs of ischemia and inflammation (ischemia-modified albumin,
eart fatty acid binding protein, myeloperoxidase), vascular
ysfunction (matrix metalloproteinase-9, pregnancy-associated
lasma protein A0, biomechanical stress (copeptin, ST2,
rowth differentiation factor [GDF]-15), hemostasis (fi-
rinogen, plasminogen activator inhibitor-1), and lipid me-
abolism (lipoprotein-associated phospholipase A2). For a
ariety of reasons, most are unlikely to reach widespread slinical use (36). Few of the novel biomarkers have been
hown to consistently improve on established markers, and
any lack confirmation in varied cohorts. In a study of 664
atients admitted with suspected ACS, for example, none of
he more than 10 novel markers tested approached the
ensitivity of cardiac troponin in diagnosing MI (71).
everal authors have proposed analytical and clinical criteria
hat novel biomarkers must successfully meet before they
an be fully integrated into clinical care (4,72,73).
Of the novel markers, GDF-15, a member of the trans-
orming growth factor family that is released by myocytes
uring ischemia and reperfusion, is one of the most prom-
sing. In several cohorts, including patients with chest pain
74) and NSTE-ACS (75,76), elevated levels of GDF-15
re associated with increased risk of death and MI, inde-
endent of ECG changes, troponin level, or NP level. In
ne study, there was an interaction between randomization
o an invasive strategy and elevated levels of GDF-15,
hich suggests that an invasive strategy may be preferential
n patients with an increased concentration (75), although
rospective confirmatory studies are needed.
roteomics, metabolomics, genomics, and pharmaco-
enomics. Advances in proteomic, metabolic, and genomic
rofiling with high-throughput screening technology com-
ined with advanced bioinformatic and statistical tech-
iques may dramatically expand the number of novel mark-
rs, traits, or patterns of cardiac metabolism and pathology.
or example, a study of serial blood samples from patients
ndergoing alcohol septal ablation, in other words a
planned MI,” revealed a specific profile of metabolites in
yrimidine metabolism, the tricarboxylic acid cycle, and the
entose phosphate pathway that were present within 10 min
f the induced MI. The pattern was also present in patients
ith ACS undergoing percutaneous coronary intervention
ut not in patients with stable coronary artery disease
CAD) undergoing percutaneous coronary intervention
77). Candidate-gene studies, which focus on predefined
enetic loci, and genomewide association studies, which
valuate hundreds of thousands of single nucleotide poly-
orphisms have identified several potential variants such as
hose at chromosome 9p21 that are associated with an
ncreased risk of incident cardiovascular disease (78–80).
urther studies are needed to determine whether individuals
ith single nucleotide polymorphisms at chromosome 9p21
re also at increased risk of secondary events after ACS.
Identification of reduced-function polymorphisms in the
ytochrome P-450 CYP2C19 gene is one of first examples of
potential treatment implications based on genetic analysis.
everal studies of patients with ACS treated with clopi-
ogrel found that the risk of recurrent ischemic events,
ncluding stent thrombosis, was greatly increased in patients
ith a reduced-function polymorphism in the gene that
ncodes CYP2C19, which is responsible for the conversion
f clopidogrel, a prodrug, into its active metabolites
81–83). Genetic testing for this allele, as well as other
ingle nucleotide polymorphisms, is commercially available,
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stration prescribing information for clopidogrel specifically
dentifies this genetic cohort as potentially not responding
o clopidogrel therapy.
maging
ith advances in technology, cardiac imaging will play a
reater role in the diagnosis of ACS and further improve
rognostic capabilities (Table 3). As with cardiac biomark-
rs, understanding the clinical history and placing the results
f any imaging modality in the context of other data are
equired to avoid misinterpretation of results.
iagnosis. No imaging test alone is either 100% sensitive
r specific for a diagnosis of ACS, and thus their clinical
tility is greatest in patients with an intermediate probability
f ACS. In patients with a high probability of ACS or MI
e.g., typical symptoms, documented CAD, elevated cardiac
iomarker level, or dynamic ECG changes), results of
maging tests are unlikely to offer incremental clinical
nformation and will only lead to unneeded exposure and
esource utilization. Conversely, in patients with a very low
robability of ACS based on other clinical features, further
esting only increases the chance of false-positive results,
equiring unnecessary follow-up testing.
SCHEMIA. To aid in the diagnosis of ACS or acute infarct,
maging modalities can evaluate either ventricular function
r coronary anatomy. Objective evidence of ischemia by
ardiac imaging reduces the time to treatment in patients
ith suspected ACS. In the urgent setting, echocardiogra-
hy is useful to identify wall-motion abnormalities in
atients with nondiagnostic ECG changes and persistent
hest discomfort. Resting myocardial perfusion imaging
MPI) in patients with ongoing chest discomfort and
ondiagnostic ECG or biomarker results will also identify
ctive ischemia. However, MPI cannot distinguish between
ecent and older infarcts; thus, abnormal MPI is not specific
or ACS. Among 2,475 patients who presented with chest
ain, randomization to a strategy with acute resting MPI
stablished and Emerging Imaging TechniquesTable 3 Established and Emerging Imaging Techniques
Imaging Modality
Diagnosis
ACS (Without Evidence of
Myocardial Necrosis) M
Coronary angiography  
Echocardiography  
Myocardial perfusion imaging 
Ischemic memory 
Computed tomography
Perfusion  
Angiography 
Cardiac magnetic resonance  
bbreviations as in Table 1.id not affect triage decisions in patients in whom the mventual clinical diagnosis was MI or unstable angina;
owever, among those patients without acute coronary
schemia (85% of the patients), MPI did reduce the rate of
dmission (84).
Both MPI with single-photon emission computed to-
ography and contrast echocardiography using molecularly
odified contrast agents have been shown to identify areas
f recent myocardial ischemia in the absence of necrosis.
ew techniques to identify recent ischemia, in other words,
n “ischemic memory,” will require further evaluation test-
ng but could improve the early diagnosis of ACS in patients
ith recent, but not ongoing, rest symptoms (85–87).
CMR has also been evaluated in the acute setting of ACS
nd extensively reviewed (88). CMR can provide substantial
nformation regarding ventricular function, ongoing isch-
mia/perfusion, early and late regions of infarction, and
oronary anatomy. In a prospective study of 162 patients
ith suspected ACS but nondiagnostic electrocardiogram
nd biomarkers, CMR had a sensitivity and specificity for
CS of 84% and 85%, respectively, which was more
ensitive than ECG or troponin and more specific than
bnormal ECG findings (89). T2-weighted images, which
dentify edema associated with acute infarcts, may also be
seful to discriminate between old and new infarcts and
ncrease the specificity and positive predictive value of CMR
n evaluating ACS (90). An added benefit of CMR is that
n more than one-half of patients who do not have ACS,
MR does identify the etiology of elevated cardiac markers
r ventricular dysfunction.
ORONARY ANATOMY. The original and gold standard
ethod to identify significant lesions is coronary angiogra-
hy, which continues to have a central role in the diagnosis
f ACS. In patients with an atypical symptoms but worri-
ome ST-segment elevation, urgent angiography will iden-
ify any potential lesions that require intervention. In
atients with persistent angina and equivocal ECG or
iomarker data, it may be better to proceed to urgent
atheterization to identify potentially electrocardiographi-
ally silent lesions rather than pursue other imaging
Prognosis Clinical Implications Monitor Therapy
  
  
 
 
 
I

odalities.
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ACS: Diagnosis and Risk Assessment April 6, 2010:1403–15Computed tomography angiography (CTA) with multi-
etector computed tomography (MDCT) technology pro-
ides excellent spatial resolution of the coronary anatomy.
lthough not yet at the same level as traditional angiography,
esolution is approaching 0.5 mm with 64-slice MDCT
echnology. In multiple studies comparing MDCT with cor-
nary angiography, the sensitivity of MCDT ranges from 73%
o 100% and the specificity from 91% to 97% (91–93).
The great challenge in incorporating imaging evidence
nto an algorithm for evaluating patients with ACS is that it
n many cases, it is difficult to determine solely based on
natomy whether a particular lesion is the cause of the
resenting symptoms. Patients may have both chest discom-
ort from a noncardiac source and a lesion on CTA that is
ot responsible for their presentation. To avoid the problem
f “true, true, and unrelated,” the clinical history must be
ompelling to act on a potential lesion detected by CTA.
imilarly, in a patient with a high probability of ACS in
hom catheterization is likely, CTA will only increase
ontrast and radiation exposure because there is less chance
f excluding disease due to the patient’s high pre-test
robability of detectable CAD and likely need for coronary
ngiography.
Thus, the greatest benefit of noninvasive CTA is to
xclude CAD in patients with a low to intermediate
robability of ACS (94). Several studies have demonstrated
hat in patients with suspected ACS, the absence of signif-
cant coronary stenosis (50%) and nonsignificant coronary
therosclerotic plaque on MDCT successfully identified
ost or all patients without ACS (up to 100% negative
redictive value), although the specificity and positive pre-
ictive value of CTA were substantially lower (94–96).
Evaluating new imaging modalities requires careful at-
ention to any potential biases in patient selection or
elective use of post-test assessment of the gold standard
atheterization, which would fundamentally, and possibly
rroneous, alter the reported performance of the new mo-
ality (97).
rognosis. A variety of data collected from cardiac imaging
an help to risk stratify patients after ACS. Assessing
schemia by a stress test in low- to intermediate-risk patients
r in patients medically managed after MI is clearly indi-
ated in practice guidelines (13,97,98). Assessment of in-
arct size, residual ischemia, and left ventricular function
ave all been shown to identify patients at greatest risk of
ecurrent ischemic events or cardiac death. Echocardiogra-
hy remains the most commonly used modality to assess
entricular function and assess for any complications of MI
ecause it is widely available; however, other modalities such
s single-photon emission computed tomography and espe-
ially CMR provide substantial information regarding in-
arct size and function (88).
ecision making. There are several treatment decisions
hat are routinely based on echocardiography, specifically
he early initiation of inhibitors of the renin-angiotensin-
ldosterone system or future consideration of implantable mardioverter-defibrillator implantation in patients with evi-
ence of depressed left ventricular function (99). As dis-
ussed previously, the absence of coronary lesions detected
n CTA can significantly improve disposition in terms of
arly discharge from an emergency department. Another
tudy using early single-photon emission computed to-
ography to quantify infarct size and residual ischemia
uggested that it may also identify patients at such low
isk of recurrent events after MI that they could be safely
ischarged early (100).
n Integrated Approach
he goal and greatest challenges are the integration of
ultiple techniques and tests into clinical practice in a
ogical and cost-effective strategy. The optimal approaches
ill include a combination of clinical, ECG, biomarker, and
maging techniques. Which individual modality to include
n a specific strategy will depend greatly on the clinical
cenario and the question that is being asked. Does this
atient have ACS or can he or she be discharged immedi-
tely? Should this patient undergo early catheterization?
hat is this patient’s risk of sudden cardiac death and
hould an implantable cardioverter-defibrillator be placed
efore discharge? Each scenario will require different tests
ut also may weigh the relative results of one particular test
ifferently depending on the clinical situation. The incor-
oration of new tools will require careful evaluation of their
echnical and clinical benefit and limitations before they are
ntegrated into practice (Table 4).
Integration of multiple test results occurs via clinical risk
cores or by combining multiple biomarkers into a multi-
arker strategy; however, there is always the conflict be-
ween simplicity of application and improved model perfor-
uestions Regarding Novel Diagnostic Tools in ACSTable 4 Questions Regarding Novel Diagnostic Tools in ACS
1. Can the tool be quantified or measured?
a. Biological relationship established
b. Accurate and reproducible method(s)
c. Preanalytical issues (including stability) evaluated and manageable
d. Technique is accessible and easy to implement
e. Widely available with rapid turnaround
f. Reasonable cost
g. Acceptable risk/side effects
2. Does tool add new information?
a. Strong and consistent association between the results of tool and
the outcomes in multiple studies
b. Information adds to or improves on existing test or replaces more
costly/risky test
c. Reference ranges and decision limits are validated in multiple studies
d. Evaluation includes data from community-based populations, and
not just clinical trial cohort
3. Will tool help the clinician to manage patients?
a. Performance superior to that of existing diagnostic tools, or
b. Improved risk stratification, or
c. Evidence that test-guided triage or therapy improves care or,
d. Evidence that associated risk is modifiable with specific therapy, or
e. Tools can be used to monitor therapy
dapted from Morrow and de Lemos (73).ance. For example, creating a binary cut point with
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April 6, 2010:1403–15 ACS: Diagnosis and Risk Assessmentiomarkers that have a linear or graded relationship with
utcome enhances clinical applicability but reduces the
iscriminatory power of that test. More complex models,
he use of Bayesian approaches, artificial neural networks, or
upport vector machines may substantially improve the
iscriminatory capacity of a particular tool or strategy. The
uestion is how easily these more sophisticated techniques
an be implemented in clinical care, especially when most
linicians may not understand the complex underlying
tatistical or decision-tree basis for the results.
There is unlikely to be one “perfect” tool that will be
ufficient to answer all the questions related to patients with
CS; however, the clinical need for improved methods to
iagnose, risk stratify, guide treatment, and evaluate therapy
emains great.
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